Pharmicell Co., Ltd. (005690)
KRX SM KRX SM Primary Summary
Pharmicell Co., Ltd. (005690) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Pharmicell Co., Ltd. ever had a stock split?
Pharmicell Co., Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Hyun-Soo Kim CEO | KRX SM Exchange | KR7005690003 ISIN |
| KR Country | - Employees | 29 Dec 2025 Last Dividend | 30 Apr 2012 Last Split | - IPO Date |
Overview
Pharmicell Co., Ltd. is a biopharmaceutical company engaged in the development and sale of stem cell drugs, with operations both locally in South Korea and internationally. The company's activities are divided into two main divisions: Biopharmaceutical Business and Biochemical Business. Initially named FcB2welve Co., Ltd., the company underwent a rebranding to Pharmicell Co., Ltd. in September 2011. Since its foundation in 1968, Pharmicell has established itself as a pioneer in stem cell therapy, holding a significant place in the biopharmaceutical industry with its headquarters in Seoul, South Korea.
Products and Services
Cellgram_AMI: This is a groundbreaking product designed for patients who have suffered from acute myocardial infarction and have undergone coronary angioplasty. It utilizes autologous bone marrow-derived mesenchymal stem cells to enhance the heart's ejection fraction.
Products under development:
- Cellgram_LC: A drug aimed at treating liver disease.
- Cellgram_ED: Developed for the treatment of impotence.
- Hearticellgram_AMI: Another cardiac disease drug, showcasing Pharmicell's commitment to combating heart-related illnesses.
- Cellgram_CKD: Focused on addressing chronic kidney disease.
- Cellgram_AKI: Designed for patients with acute kidney disease.
Beyond therapeutics, Pharmicell Co., Ltd. is involved in the biochemical sector, where it engages in the development and production of intermediates of raw material medicines, including nucleosides and mPEGs. The company also produces materials with a low dielectric constant, eco-friendly flame retardants, polyol synthesis catalysts, and PET catalysts, among other chemical products.
In the realm of support and auxiliary products and services:
- Half-Serum DMEM: Providing essential materials for research and development in the biotechnology and pharmaceutical industries.
- Clinical Development and Commercialization Services: Offering comprehensive solutions for the development and commercial launch of new drugs.
- Twelve Stem Cell Bank: Operating a stem cell bank, underpinning the importance of stem cell storage and availability for future therapeutic use.
- Stem Cell Culture Media Cosmetics: Leveraging stem cell technology for cosmetic products, highlighting the company's diverse application of its biotechnological expertise.
